Pages that link to "Q38449686"

The following pages link to The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk (Q38449686):

Displaying 9 items.

• A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity (Q24615651) (← links)
• Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies (Q27026351) (← links)
• Anti-inflammatory effects of Polygonum minus (Huds) extract (Lineminus™) in in-vitro enzyme assays and carrageenan induced paw edema (Q34274400) (← links)
• Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008 – a retrospective patient record review (Q34418355) (← links)
• "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients". (Q35136952) (← links)
• Risk of stroke associated with nonsteroidal anti-inflammatory drugs (Q37464386) (← links)
• Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and Prevention (Q37800668) (← links)
• Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs (Q38760434) (← links)
• Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells (Q42199704) (← links)